Secukinumab: A Silver Lining in Dermatology

Simple item page
dc.contributor.authorManoharan, Den_US
dc.contributor.authorN., RVen_US
dc.contributor.authorShreya, Sen_US
dc.contributor.authorSuzsmi, L.S.en_US
dc.date.accessioned2023-06-17T07:12:23Z
dc.date.available2023-06-17T07:12:23Z
dc.date.issued2022-07
dc.description.abstractSecukinumab, a fully human monoclonal antibody, is a biological agent that targets interleukin-17A. Secukinumab is used in the management of the common dermatological entity - plaque-type psoriasis and its various types, namely psoriatic arthritis, hypertrophic palmoplantar psoriasis and generalized pustular psoriasis. Other less common indications of this popular interleukin -17A inhibitor, secukinumab include ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, Familial Mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). This review article was written by referring to various review articles, original articles, and some books related to highly regarded databases, such as the Web of Science, PubMed, and Scopus. The keywords explored during review of literature consisted of combinations of the following words: human monoclonal antibody, IL-17A, and biologicals. The authors with this in-depth review hope to explore the working of this versatile biological, Secukinumab, especially as a silver lining in dermatologyen_US
dc.identifier.affiliationsDepartment of Dermatology, Venereology and Leprosy, Sree Balaji Medical College and Hospitals, Bharath University, Chrompet, Chennai, Tamil Nadu, India.en_US
dc.identifier.citationManoharan D, N. RV, Shreya S, Suzsmi L. S.. Secukinumab: A Silver Lining in Dermatology. Journal of Pharmacology and Pharmacotherapeutics. 2022 Jul; 13(2): 119–124en_US
dc.identifier.issn0976-500X
dc.identifier.issn0976-5018
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/216055
dc.languageenen_US
dc.publisherSAGE Publicationsen_US
dc.relation.issuenumber2en_US
dc.relation.volume13en_US
dc.source.urihttps://doi.org/10.1177/0976500X221105921en_US
dc.subjectSecukinumaben_US
dc.subjectIL-17A inhibitoren_US
dc.subjectHuman monoclonal antibodyen_US
dc.subjectBiologicalsen_US
dc.subjectPsoriasisen_US
dc.subjectPsoriatic arthritisen_US
dc.titleSecukinumab: A Silver Lining in Dermatologyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JPP2022v13n2p119.pdf
Size:
302.52 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmacology and Pharmacotherapeutics